Abstract
Background There have been no published genome-wide studies of the genetics of cancer- and treatment-related cognitive decline (CRCD); the purpose of this study is to identify genetic variants associated with CRCD in older female breast cancer survivors.
Methods Analyses included white non-Hispanic breast cancer women with non-metastatic breast cancer aged 60+ (N=325) and age-, racial/ethnic group, and education-matched controls (N=340) with pre-systemic treatment and one-year follow-up cognitive outcomes. CRCD was assessed using longitudinal domain scores on neurocognitive tests of Attention, Processing speed, and Executive function (APE), and Learning and Memory (LM). Linear regression models of one-year cognition included an interaction term for SNP or gene SNP enrichment*cancer case/control status, controlling for demographic variables and baseline cognition.
Results Cancer patients carrying minor alleles for two SNPs, rs76859653 (chromosome 1) in the hemicentin 1 (HMCN1) gene (p=1.624×10−8), and rs78786199 (chromosome 2, p=1.925×10−8) in an intergenic region had lower one-year APE scores than non-carriers and controls. Gene-level analyses showed the POC5 centriolar protein gene was enriched for SNPs associated with differences in longitudinal LM performance between patients and controls.
Conclusion The SNPs associated with cognition in survivors, but not controls, were members of the cyclic nucleotide phosphodiesterase family, which play important roles in cell signaling, cancer risk, and neurodegeneration. These findings provide preliminary evidence that novel genetic loci may drive susceptibility to CRCD.
Competing Interest Statement
Saykin: Receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board, unrelated to breast cancer or the present study); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). All other authors declare no relevant conflicts of interest
Funding Statement
This research and the authors effort were supported by National Cancer Institute at the National Institutes of Health (NIH) grants R01CA129769 and R35CA197289 to JM. This study was also supported in part by National Institute on Aging at the National Institutes of Health grant R01AG068193 to JSM and AJS and by National Cancer Institute at the National Institutes of Health grant P30CA51008 to Georgetown Lombardi Comprehensive Cancer Center for support of the Biostatistics and Bioinformatics Resource and the Non-Therapeutic Shared Resource. The work of AJS and BCM was supported in part by National Institute on Aging, National Library of Medicine, and National Cancer Institute at the National Institutes of Health grants P30AG10133/P30AG072976, R01AG19771, R01LM01136, R01CA244673, U01AG068057, and T32AG071444. TAA and JCR were supported in part by National Cancer Institute at the National Institutes of Health grants R01CA218496, R01CA172119, R03CA249548, and P30CA008748. TAA was also supported by U54CA137788. The work of JC was supported in part by the American Cancer Society Research Scholars grant 128660-RSG-15-187-01-PCSM and National Institute on Aging and National Cancer Institute at the National Institutes of Health grants R01CA237535 and R56AG068086. HJC was supported in part by the National Institute on Aging at the National Institutes of Health grant P30AG028716 for the Duke Pepper Center. SKP was supported in part by the American Cancer Society Research Scholars grant RSG-17-023-01-CPPB, and the National Institutes of Health grant R01CA261793. KN was supported in part by National Institute on Aging, National Library of Medicine, and National Cancer Institute at the National Institutes of Health grants P30AG10133/P30AG072976.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Indiana University Institutional Review Board reviewed and approved this protocol (most recent approval date June 7, 2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DISCLAIMER
The views and opinions expressed are those of the authors and do not necessarily represent the official position of the National Cancer Institute.
The authors thank the participants of the Thinking and Living with Cancer Study, their families, and study site staff. We are particularly grateful to the TLC participants for their time and effort; this research would not have been possible without their generosity and willingness to participate during a very challenging time in their lives.
Preliminary results of this study with smaller subsets of subjects were presented at the International Cognition and Cancer Task Force Meetings, 2018 (Seattle) and 2020 (Denver)
Data Availability
All data is available on request from the corresponding author.
